Targeted therapy proves effective against aggressive rare blood cancer
Wednesday, April 24, 2019 - 18:00
in Health & Medicine
Clinical study treating BPDCN with tagraxofusp led to first FDA approval for the disease.
Updated by artificial intelligence Tue, 13 Jun 2023, 2:53:47 UTC Learn more
- Tell your friends
- Get science news via